E-MAIL UPDATES

Click here to join
our Electronic Communications.

Investors & Media

Whats new.

Press releases

Press releases.

Immutep Expands Part B of TACTI-002 Collaboration Trial

March 5th 2021
press releases

Immutep Announces Advancement Of Phase II Trial For Eftilagimod Alpha In Covid-19 Patients To Randomised Portion Of The Study

January 27th 2021
press releases

Immutep Quarterly Activities Report & Appendix 4C

January 22nd 2021
press releases
more

Investor updates

Investor updates.

Investor Update - August 2020

August 17th 2020
investor updates

Investor Update - November 2019

November 22nd 2019
investor updates

Investor Update - January 2019

January 31st 2019
investor updates
more

Analyst reports

Analyst reports.

Bell Potter - Stage 2 of 2nd line NSCLC patient cohort in Phase 2 TACTI-002 trial starts recruitment (Analyst: Tanushree Jain)

For a copy of this research report please contact your Bell Potter advisor.

March 5th 2021
analyst reports

Bell Potter - 1H21 Results broadly in-line (Analyst: Tanushree Jain)

For a copy of this research report please contact your Bell Potter advisor for the report.

February 25th 2021
analyst reports

Bell Potter - Strong balance sheet with several catalysts (Analyst: Tanushree Jain)

For a copy of this research report please contact tnjain@bellpotter.com.au

February 5th 2021
analyst reports
more